Screener
ANI Pharmaceuticals ANIP Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Operating Expenses, net | 225,584 | 197,479 | 424,158 | 368,407 |
| Operating income | 40,460 | 13,892 | 79,348 | 40,086 |
| Other (expense) income, net | ||||
| Unrealized gain (loss) on investment in equity securities | 741 | 332 | 6,494 | (589) |
| Interest expense, net | (3,636) | (5,438) | (7,405) | (10,922) |
| Other (expense) income, net | (468) | 1,739 | (1,119) | 1,937 |
| Income Before Income Tax Expense | 37,097 | 10,525 | 77,318 | 30,512 |
| Income tax expense | 12,386 | 1,976 | 23,115 | 6,282 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's net gains (losses) on investments?
- ANI Pharmaceuticals (ANIP) reported net gains (losses) on investments of $741K in Q2 2026.
- How has ANI Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- ANI Pharmaceuticals's net gains (losses) on investments increased by 123.2% year-over-year, from $332K to $741K.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about ANI Pharmaceuticals's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude